Talbot Financial LLC Increases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Talbot Financial LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 98,503 shares of the company’s stock after purchasing an additional 3,902 shares during the period. Johnson & Johnson comprises about 1.9% of Talbot Financial LLC’s portfolio, making the stock its 16th biggest position. Talbot Financial LLC’s holdings in Johnson & Johnson were worth $15,963,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in JNJ. SL Advisors LLC acquired a new position in shares of Johnson & Johnson in the third quarter worth $327,000. Brookstone Capital Management boosted its holdings in Johnson & Johnson by 5.5% in the third quarter. Brookstone Capital Management now owns 73,811 shares of the company’s stock valued at $11,962,000 after purchasing an additional 3,842 shares during the period. O Keefe Stevens Advisory Inc. grew its stake in Johnson & Johnson by 4.5% during the 3rd quarter. O Keefe Stevens Advisory Inc. now owns 3,659 shares of the company’s stock worth $593,000 after purchasing an additional 156 shares in the last quarter. Country Trust Bank increased its holdings in Johnson & Johnson by 4.3% during the 3rd quarter. Country Trust Bank now owns 201,872 shares of the company’s stock worth $32,715,000 after purchasing an additional 8,255 shares during the period. Finally, FCF Advisors LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at about $9,423,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $159.64 on Wednesday. The stock has a market cap of $384.20 billion, a P/E ratio of 9.95, a P/E/G ratio of 2.69 and a beta of 0.52. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The stock has a 50 day moving average of $162.62 and a two-hundred day moving average of $154.33. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter in the prior year, the firm earned $2.80 EPS. Johnson & Johnson’s revenue for the quarter was up 4.3% on a year-over-year basis. On average, research analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.11%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on JNJ. TD Cowen cut their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Morgan Stanley raised their price target on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. Finally, The Goldman Sachs Group lowered their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $173.43.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.